Dr. Roger Macklis, a radiation oncologist at Cleveland Clinic, has for years agitated for an expanded role for radioimmunotherapy — not just Zevalin, but also for its competitor Bexxar.

Cleveland Clinic oncologist Roger Macklis has for some time supported the owners of the underachieving drug Zevalin as a fresh way to treat lymphatic cancer: Piggyback that drug on other chemotherapy drugs to increase the effectiveness of initial treatments. A regulatory change could happen in July that fulfills Macklis’ mission for greater use of drugs like Zevalin.